Form 4: Bicycle Therapeutics Officer Receives Equity, Sells Shares for Tax

Bicycle Therapeutics' Chief Product & Supply Chain Officer, Michael Charles Ferguson Hannay, was granted 50,000 restricted share units and 100,000 stock options, while also selling shares to cover tax obligations.

Summary

• Michael Charles Ferguson Hannay, Chief Product & Supply Chain Officer, was granted 50,000 Restricted Share Units (RSUs) on January 2, 2026.
• One-fourth (12,500) of these RSUs will vest on January 2, 2027, with the remainder vesting in 12 equal quarterly installments thereafter.
• Hannay also received an Employee Stock Option to buy 100,000 ordinary shares at an exercise price of $7.08 on January 2, 2026.
• One-fourth (25,000) of the stock options will vest on January 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, expiring on January 2, 2036.
• To cover statutory tax withholding obligations related to RSU vesting and settlement, Hannay sold 2,827 ordinary shares on January 2, 2026, at a weighted average price of $6.80 (ranging from $6.62 to $7.11).
• Additionally, 2,367 ordinary shares were sold on January 5, 2026, at a weighted average price of $6.45 (ranging from $6.30 to $6.70) for the same tax purposes.
• Following these transactions, Hannay beneficially owns 97,908 ordinary shares and 100,000 employee stock options.
• These "sell to cover" transactions were mandated by the award agreement and were not discretionary sales.

Sentiment

Score: 7

Explanation: The filing indicates a positive long-term commitment from a key executive through significant equity grants, which is generally favorable. The sales are non-discretionary for tax purposes, mitigating any negative sentiment typically associated with insider selling.

Positives

• Grant of 50,000 Restricted Share Units (RSUs) to a key officer, aligning management interests with shareholder value.
• Grant of 100,000 Employee Stock Options with an exercise price of $7.08, providing long-term incentive.

Negatives

• Sale of 5,194 ordinary shares (2,827 + 2,367) by a key officer, although these were non-discretionary "sell to cover" transactions for tax obligations.

Future Outlook

The filing details future vesting schedules for both Restricted Share Units and Employee Stock Options, with initial vesting for both occurring on January 2, 2027, and subsequent vesting over several years, indicating a long-term incentive structure for the officer.

Industry Context

This Form 4 filing reflects standard executive compensation practices within the biotechnology or pharmaceutical industry, where equity grants like RSUs and stock options are common tools to attract, retain, and incentivize key personnel, aligning their long-term interests with company performance. The 'sell to cover' transaction is also a routine mechanism for managing tax obligations associated with equity vesting.

Related Party Transactions

• The transactions involve equity grants and sales by Michael Charles Ferguson Hannay, Chief Product & Supply Chain Officer, which are considered related party transactions as part of executive compensation.

Stakeholder Impact

• Shareholders: The equity grants align the interests of a key executive with long-term shareholder value. The "sell to cover" transactions are routine and not indicative of a lack of confidence.
• Employees: Reflects standard executive compensation practices, potentially setting a precedent or benchmark for other senior roles.

Next Steps

• One-fourth of the 50,000 Restricted Share Units will vest on January 2, 2027, with the remainder vesting in 12 equal quarterly installments thereafter.
• One-fourth of the 100,000 Employee Stock Options will vest on January 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter.

Key Dates

Recommendation

The filing details routine executive compensation events, including equity grants and non-discretionary 'sell to cover' transactions for tax purposes. These actions do not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment stance. The grants indicate continued executive alignment with long-term company performance, which is a neutral to slightly positive signal, but not enough to change a 'hold' position based solely on this filing.

Keywords

Bicycle Therapeutics, BCYC, SEC Form 4, Insider Trading, Stock Options, Restricted Share Units, Executive Compensation, Sell to Cover, Michael Charles Ferguson Hannay